Seagen has been pioneering novel technologies to treat cancer for more than 20 years.
As a pioneer in antibody–drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. Our research team is highly motivated to build an innovative pipeline of transformative cancer therapeutics accelerated by best-in-class technology platforms. Our science is inspired by a singular mission—to make a real difference for people impacted by cancer.
Today, our research efforts are dedicated to advancing a pipeline of:
Science that’s focused on patients first
At Seagen, we employ rigorous science to discover novel transformational medicines for cancer patients. Our Translational Sciences team acts as the bridge between research and clinical development, innovating in both science and process to accelerate the development of therapies that can make a meaningful difference for patients.
What we learn in the clinic, we leverage to improve future drug design. As a team and an organization, we thrive on scientific challenge and strive to deliver transformational therapies for patients. We’re committed to finding the right drug, for the right patient, at the right dose and schedule, as quickly as possible.
Revolutionary technologies with real impact
Seagen is an industry leader in innovative, targeted drug delivery. ADC technology harnesses the power of potent payloads and the specificity of antibodies to selectively deliver small molecule drugs to tumors. Our proprietary ADC technologies are designed to target cancer cells with greater precision, reducing side effects.
We’re also leveraging our sugar-engineered antibody (SEA)-empowered technology to build a portfolio of proprietary, empowered immuno-oncology agents that can target hematologic malignancies and solid tumors.